The online version of this article (doi:10.1186/1758-5996-6-92) contains supplementary material, which is available to authorized users.
The authors declare that they have no competing interests.
N-AT conceived, designed and supervised the study, reviewed and edited the manuscript. MHA designed the study, researched data, contributed to the discussion and wrote the manuscript. MHD conceived and designed the study, researched data, contributed to the discussion and reviewed the manuscript. KAT and NO researched data. All authors read and approved the final manuscript.
Several studies have reported that the metabolic syndrome (MS) is more common in subjects with HIV infection than in HIV-negative individuals. HIV infection and the use of Highly Active Antiretroviral Therapy (HAART) have been shown to predispose HIV-infected persons to MS. In this study, we report the prevalence of MS in Cameroonian HIV-infected subjects receiving different combinations of HAART as well as HIV patients who have never received antiretroviral drugs.
In this cross-sectional study, 173 treated and untreated HIV-infected out-patients (aged 18–70 years) managed at the Buea and Limbe Regional Hospitals and 50 seronegative individuals (controls) were recruited after obtaining their consent. Ethical approval for this study was obtained from the National Ethics Committee of Cameroon. Metabolic syndrome prevalence was examined using the U.S. National Cholesterol Education Program Adult Treatment Panel III (ATPIII) criteria. Data was analyzed using SPSS® (Statistical Package for the Social Sciences, SPSS Inc., Chicago, IL, USA) version 16. Statistical significance was set at p < 0.05.
The prevalence of MS among the HIV patients was 15.6% (27/173) and 8% (4/50) among the controls and the difference was significant (p = 0.022). MS was more prevalent in HIV-infected patients on HAART than in ART-naive patients and seronegative individuals. Overall, the prevalence of MS was significantly higher (p = 0.003) in females (28/153; 18.3%) than in males (3/70; 4.3%). The patients on first-line drugs demonstrated the highest MS prevalence (15/62; 24.2%) followed by the ART-naïve group of patients (7/61; 11.5%) and the lowest prevalence was among the patients on protease inhibitors (5/50; 10%). Patients on the drug combination Lamivudine/Stavudine/Nevirapine had the highest prevalence of MS (50%).
In this study, HAART but not HIV disease plays a significant role in the development of MS. The metabolic complications as a result of treatment with HAART may predispose HIV patients to developing cardiovascular diseases and diabetes, in spite of improvements in morbidity and mortality conferred by immune reconstitution as a result of HAART treatment.
Authors’ original file for figure 113098_2014_355_MOESM1_ESM.pdf
Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998, 338: 853-860. 10.1056/NEJM199803263381301. CrossRefPubMed
Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA: A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998, 12: 51-58. 10.1097/00002030-199807000-00003. CrossRef
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J Am Med Assoc. 2001, 285: 2486-2497. 10.1001/jama.285.19.2486. CrossRef
Bruno R, Gazzaruso C, Sacchi P, Zocchetti C, Giordanetti S, Garzaniti A, Ciappina V, Maffezzini E, Maserati R, Filice G: High prevalence of metabolic syndrome among HIV infected patients: link with the cardiovascular risk. J Acquir Immune Defic Syndr. 2002, 31: 363-365. 10.1097/00126334-200211010-00015. CrossRefPubMed
Palella F, Wang Z, Chu H: Presented at: Third International AIDS Society Conference on HIV Pathogenesis and Treatment. Correlates and prevalence of the metabolic syndrome over time in the Multicenter AIDS Cohort Study [abstract TuPe2.2B18]. 2005, Rio de Janeiro: International Association of Physicians in AIDS Care (IAPAC), 2006,12:9
Grunfeld C, Pang M, Schimizu L, Shigenaga JK, Jensen P, Feingold KR: Resting energy expenditure, caloric intake, and short-term weight change in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Am J Clin Nutr. 1992, 55: 455-460. PubMed
Jericŏ C, Hernando K, Milagros M, Jordi O, Ana G, Juan L, Pere S, Jose LJ: Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors. Diabetes Care. 2005, 28: 123-127.
Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972, 18: 499-502. PubMed
Jacobson DL, Tang AM, Spiegelman D, Thomas AM, Skinner S, Gorbach S, Wanke C: Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey). J Acquir Immune Defic Syndr. 2006, 43: 458-466. 10.1097/01.qai.0000243093.34652.41. CrossRefPubMed
Bonfanti P, Giannattasio C, Ricci E, Facchetti R, Rosella E, Franzetti M, Cordier L, Pusterla L, Bombelli M, Sega R, Quirino T, Mancia G: HIV and metabolic syndrome: a comparison with the general population. J Acquir Immune Defic Syndr. 2007, 45: 426-431. 10.1097/QAI.0b013e318074ef83. CrossRefPubMed
Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A: Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using international diabetes foundation and adult treatment panel III criteria. Diabetes Care. 2007, 30: 113-119. 10.2337/dc06-1075. CrossRefPubMed
Ivana K, Ariana V, Branka S, Mladen S, Josipa K, Silvije V: Metabolic syndrome in a metapopulation of Croatian Island isolates. Croat Med J. 2006, 47: 585-592.
Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK: Efficacy and safety of tenofovir df vs stavudine in combination therapy in antiretroviral-naïve patients. J Am Med Assoc. 2004, 292: 191-201. 10.1001/jama.292.2.191. CrossRef
- Prevalence of metabolic syndrome in human immunodeficiency virus - infected patients from the South-West region of Cameroon, using the adult treatment panel III criteria
Herbert Afegenwi Mbunkah
Henry Dilonga Meriki
Anthony Tufon Kukwah
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II